Ustekinumab combined with upadacitinib promotes endoscopic healing in moderate-to-severe Crohn's disease with anti-TNF-α failure.
BACKGROUND Anti-tumor necrosis factor-α (TNF-α) therapy failure in moderate-to-severe Crohn's disease (CD) represents a major clinical challenge. However, the exploration of advanced combination therapy offers a promising direction. This study compared the efficacy of ustekinumab (UST) plus upadacitinib (UPA) with eith...